人乳腺浸润性导管癌端粒酶活性的检测

目的比较乳腺浸润性导管癌及乳腺良性病变组织端粒酶活性的异同,探讨端粒酶活性在恶性肿瘤诊断中的意义。方法用端粒酶重复扩增法（ＴＲＡＰ）检测了６１例乳腺浸润性导管癌及１４例乳腺良性病变组织端粒酶活性。结果６１例中４９例（８０％）显示端粒酶活性,端粒酶活性与浸润性导管癌的分级、肿瘤大小、淋巴结转移及肿瘤组织雌激素受体及孕激素受体表达无关。５例乳腺囊腺病无一例端粒酶活性,９例乳腺腺瘤中４例端粒酶弱阳性。结论端粒酶活性见于绝大多数乳腺浸润性导管癌及极少数的乳腺腺病中,该酶活性可能在乳腺癌的发生发展中起重要作用

Telomerase activity in infiltration ductal carcinoma of breast

Objectives To compare telomerase activity of infiltration ductal carcinoma of breast with that of benign breast changes and to analyze the significance of telomerase activity in diagnosis of malignancy. Method Telomerase activity was detected in 61 cases of infiltration ductal carcinomas of breast and 14 cases of benign changed breast using TRAP assay. Results Telomerase activity was detected in 49 of 61 (80.3%) cases of infiltration ductal carcinoma. Telomerase activity in infiltration ductal carcinoma was not related tumor grades, tumor size, lymph node metastasis status, even tumor tissue estogen receptor(ER) and progesterone receptor(PR) status.Telomerase activity was not present in 5 cases of breast fibrocystic disease. Weak telomerase activity was detected in 4 of 9 cases of breast fibroadenoma. These suggested that telomerase activity acquires in very early stage of breast cancer.Conclusion Telomerase activity is only detected in most of infiltration ductal carcinomas of breast and few cases of fibroadenoma. Telomerase activity may play an important role in the development of breast cancer.